International Association for the Study of Lung Cancer (IASLC) shared a post on LinkedIn:
“New data highlight a significant advance in ES-SCLC treatment.
According to lead investigator Dr. Kelly Paulson, the combination of tarlatamab and anti–PD-L1 therapy showed unprecedented overall survival while maintaining a manageable safety profile in patients with extensive-stage small cell lung cancer.
Read the full details in ILCN.”
More posts featuring IASLC.